Menu
Recruiting NCT06903741

New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye

Phase IV Interventional Dry Eye Disease (DED)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: T2769.
Who it may be relevant to
Registry conditions: Dry Eye Disease (DED). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Bulgaria
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Effect of a New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) on Dry Eye Disease and Patient Quality of Life

Overview

The goal of this prospective, non-randomized, non-comparative, monocentric PMCF study is to assess the performance of a new preservative-free combination of trehalose, sodium hyaluronate and NAAGA on DED at 6 months in 30 patients having dry eye disease. The main questions it aims to answer are: * To assess the performance and safety of T2769 at 3 months and 6 months. * To assess patient compliance to therapy. * To assess the occurrence of dry eye flares. Participants will be asked to use T2769 on a daily basis and complete a self-questionnaire throughout the study.

Interventions

  • Device T2769
    Preservative-free combination of trehalose, sodium hyaluronate and N-acetyl-aspartyl-glutamate

Primary outcome measures

  • Improvement of DED signs and symptoms at 6 months (M6) according to Ocular Surface Disease Index (OSDI) score change from baseline to M6 [Time frame: at baseline, at 3 months, at 6 months]

Eligibility criteria

Inclusion criteria

  • Men and women aged over 18 years,
  • Able to give written informed consent prior the initiation of any procedure,
  • History of dry eye syndrome for at least 3 months,
  • OSDI ≥13,
  • Never been treated with artificial tears or with no artificial tears at least 1 month before the enrolment, or not satisfied with current artificial tears.

Exclusion criteria

Systemic/non Ophthalmic Exclusion Criteria

  • Known or suspected hypersensitivity to one of the components of the IMD,
  • History of or active relevant systemic condition incompatible with the investigation or likely to interfere with the investigation results or the patient safety according to investigator judgment.

Specific Exclusion Criteria Regarding Childbearing Potential Women

  • Pregnant or breast-feeding women,
  • Childbearing potential women neither surgically sterilised nor using an adequate contraception (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant, vaginal ring, patch) .

Exclusion Criteria Related to General Conditions

  • Alcohol addiction and heavy smoker according to investigator's judgement,
  • Unable to understand the investigation procedures or to give informed consent,
  • Non-compliant (e.g., not willing to attend a visit or completing the self-questionnaire; way of life interfering with compliance),
  • Participant in this investigation at the same time as another clinical investigation/study,
  • Participant in this investigation within the exclusion period of a previous study/investigation with a minimum of one month,
  • Participant being institutionalized because of legal or regulatory order, inmate of psychiatric wards, prison or state institutions, or employee or family member of the investigation sites or of the Sponsor's company.

Exclusion criteria related to previous and concomitant treatments (medications/non-medicinal therapies/procedures)

  • Participant with previous, current or anticipated prohibited listed treatment (or prohibited modification of treatment regimen).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Bulgaria · 1 center
  • Group Practice Outpatient Clinic for Specialized Medical — Varna

Identifiers

NCT: NCT06903741 · LT2769-006

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗